India: More than a month after Johnson & Johnson announced that it will stop the sale of its talc-based baby powder globally in 2023, the Indian state of Maharashtra cancelled the manufacturing license of the pharmaceutical company.
Reportedly, the state’s Food & Drug Administration (FDA) cancelled the company’s license to manufacture the baby powder citing an inspection where it found its premier baby product to be sub-standard in quality.
The agency collected samples from Pune and Nashik for quality checks and found the pH value of the powder to be much higher than the permissible levels.
Consequently, the US-based company was issued a show-cause notice and ordered to recall all its stocks as the use of the product could affect the health and skin of newborn babies, according to an FDA statement.
Johnson & Johnson, however, refused to accept the FDA’s report and informed that it will challenge it in court. Moreover, the company argued that the sample be sent to the referral laboratory i.e. Central Drugs Laboratory, Govt. of India, Kolkata.